Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 20Neoplasms 9Advanced Malignant Neoplasm 9Keratosis, Actinic 8Skin Diseases 5Keratosis 5Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Preleukemia 2Pathologic Processes 2Neoplasms by Site 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Hormone Receptor Positive Malignant Neoplasm of Breast 2Hematologic Diseases 2Endometrial Neoplasms 2Carcinoma 2Breast Neoplasms 2Bone Marrow Diseases 2Biochemical Recurrence of Malignant Neoplasm of Prostate 2Uterine Prolapse 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Thrombocythemia, Essential 1Syndrome 1

Interventions

toripalimab 1potassium oxonate 1gimeracil 1apatinib 1Tegafur 1Nivolumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Neoplasms of Digestive Organs × Other neoplasm × Clear all
NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡